Invest
27 Years
4.4 Star
1 Crore +
Pharmaceuticals company Lupin announced Q4FY24 results:
Financial Highlights:
- Gross Profit was Rs 33,213 million compared to Rs 33,538 million in Q3FY24, with gross margin of 67.8%.
- Personnel cost was 18.4% of sales at Rs 9,002 million compared to Rs 8,892 million in Q3FY24.
- Manufacturing and other expenses were 30.4% of sales at Rs 14,901 million compared to Rs 15,602 million in Q3FY24.
- PBT was lower in Q4FY24 on account of impairment charge of Rs 2,013 million.
- Investment in R&D for the quarter was Rs 4,255 million (8.7% of sales).
- Operating working capital was Rs 56,913 million as on March 31, 2024.
- Capital Expenditure for the quarter was Rs 1,059 million.
- Net Debt as on March 31, 2024 stands at Rs 4,766 million.
- Net Debt-Equity as on March 31, 2024 stands at 0.03.
Commenting on the results, Nilesh Gupta, Managing Director, Lupin Limited said, “We continue to move forward with sustainable and profitable growth and delivered another strong set of numbers in Q4. Our U.S. sales remain healthy driven by inhalation products, and our India formulation business is delivering ahead of market. While FY24 has been a year of resurgence for the company, we look forward to an even stronger FY25 driven by growth across our key geographies and consistent improvement in our margins”.
FAQ’s on Lupin Ltd Shares
